We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
- Authors
Kobayashi, Kazuo; Toyoda, Masao; Tone, Atsuhito; Kawanami, Daiji; Suzuki, Daisuke; Tsuriya, Daisuke; Machimura, Hideo; Shimura, Hidetoshi; Takeda, Hiroshi; Yokomizo, Hisashi; Takeshita, Kei; Chin, Keiichi; Kanasaki, Keizo; Miyauchi, Masaaki; Saburi, Masuo; Morita, Miwa; Yomota, Miwako; Kimura, Moritsugu; Hatori, Nobuo; Nakajima, Shinichi
- Abstract
Aims: Combination therapy with sodium-glucose cotransporter inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1Ras) is now of interest in clinical practice. The present study evaluated the effects of the preceding drug type on the renal outcome in clinical practice. Methods: We retrospectively extracted type 2 diabetes mellitus patients who had received both SGLT2i and GLP1Ra treatment for at least 1 year. A total of 331 patients in the GLP1Ra-preceding group and 312 patients in the SGLT2i-preceding group were ultimately analyzed. Either progression of the albuminuria status and/or a ≥30% decrease in the eGFR was set as the primary renal composite outcome. The analysis using propensity score with inverse probability weighting was performed for the outcome. Results: The incidences of the renal composite outcome in the SGLT2i- and GLP1Ra-preceding groups were 28% and 25%, respectively, with an odds ratio [95% confidence interval] of 1.14 [0.75, 1.73] (p =.54). A logistic regression analysis showed that the mean arterial pressure (MAP) at baseline, the logarithmic value of the urine albumin-to-creatinine ratio at baseline, and the change in MAP were independent factors influencing the renal composite outcome. Conclusion: With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome.
- Subjects
TYPE 2 diabetes; SODIUM-glucose cotransporters; GLUCAGON-like peptide-1 agonists; LOGISTIC regression analysis; DRUGS; SODIUM-glucose cotransporter 2 inhibitors; GLUCAGON-like peptide 1
- Publication
Diabetes & Vascular Disease Research, 2023, Vol 20, Issue 6, p1
- ISSN
1479-1641
- Publication type
Article
- DOI
10.1177/14791641231222837